Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
CohBar reports Q3 EPS (5c), consensus (8c) » 16:08
11/15/21
11/15
16:08
11/15/21
16:08
CWBR

CohBar

/

+

The company had cash and…

The company had cash and investments of $15M as of September 30, compared to $21M as of December 31, 2020. The cash burn for the quarter ended September 30, 2021, was approximately $3.3M. "We were pleased to report positive topline data from our first clinical study this past quarter and believe that this data not only demonstrates the potential of our CB4211 program but also validates our unique approach of creating novel therapeutics sourced from the mitochondrial genome," stated Dr. Joseph Sarret, Chief Executive Officer. "With a strengthened balance sheet from our recent financing, we are now well-positioned to continue to advance our pipeline."

ShowHide Related Items >><<
CWBR CohBar
/

+

CWBR CohBar
/

+

11/12/21 Cantor Fitzgerald
CohBar initiated with an Overweight at Cantor Fitzgerald
11/12/21 Cantor Fitzgerald
CohBar initiated with an Overweight at Cantor Fitzgerald
08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
CWBR CohBar
/

+

  • 28
    Oct
Initiation
CohBar initiated with an Overweight at Cantor Fitzgerald » 07:40
11/12/21
11/12
07:40
11/12/21
07:40
CWBR

CohBar

/

+

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of CohBar with an Overweight rating and $2.50 price target. With plansto report more data from CB4211 as a late-breaker at AASLD in November, and launch of Phase 2 studies next year, Kluska believes it is a good time to look at the stock, the analyst tells investors in a research note. Kluska feels her model assumptions are very conservative at this stage and sees significant potential upside opportunities.

ShowHide Related Items >><<
CWBR CohBar
/

+

CWBR CohBar
/

+

11/12/21 Cantor Fitzgerald
CohBar initiated with an Overweight at Cantor Fitzgerald
08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
CWBR CohBar
/

+

  • 28
    Oct
Initiation
CohBar initiated with an Overweight at Cantor Fitzgerald » 06:19
11/12/21
11/12
06:19
11/12/21
06:19
CWBR

CohBar

/

+

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of CohBar with an Overweight rating and $2.50 price target.

ShowHide Related Items >><<
CWBR CohBar
/

+

CWBR CohBar
/

+

08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
03/31/21 Chardan
CohBar price target raised to $3.50 from $3.00 at Chardan
CWBR CohBar
/

+

  • 28
    Oct
Over a month ago
Syndicate
CohBar 20.83M share Spot Secondary priced at 72c » 08:51
10/28/21
10/28
08:51
10/28/21
08:51
CWBR

CohBar

/

+

Cantor Fitzgerald acted…

Cantor Fitzgerald acted as lead book running manager for the offering.

ShowHide Related Items >><<
CWBR CohBar
/

+

CWBR CohBar
/

+

08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
03/31/21 Chardan
CohBar price target raised to $3.50 from $3.00 at Chardan
CWBR CohBar
/

+

  • 28
    Oct
Syndicate
CohBar files to sell common stock and warrants, no amount given » 16:02
10/27/21
10/27
16:02
10/27/21
16:02
CWBR

CohBar

/

+

Cantor Fitzgerald &…

Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering, and Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as co-manager.

ShowHide Related Items >><<
CWBR CohBar
/

+

CWBR CohBar
/

+

08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
03/31/21 Chardan
CohBar price target raised to $3.50 from $3.00 at Chardan
CWBR CohBar
/

+

Hot Stocks
CohBar announces presentation of CB4211 Phase 1a/1b results » 09:06
10/13/21
10/13
09:06
10/13/21
09:06
CWBR

CohBar

/

+

CohBar announced that…

CohBar announced that data from its CB4211 Phase 1a/1b clinical study have been selected for presentation during the late-breaking poster session at The American Association for the Study of Liver Diseases, or AASLD, Annual Meeting. This event will be held virtually on November 12 - 15, 2021. The presentation will discuss further details from the Phase 1a/1b clinical study of CB4211 in obese subjects with nonalcoholic fatty liver disease. In August 2021, the company announced positive topline data from the trial, including statistically significant reductions in ALT, AST and glucose compared to placebo after 4 weeks of treatment with CB4211. CB4211 is under development for the treatment of nonalcoholic steatohepatitis and obesity. Presentation Title: "CB4211, a Novel Analog of MOTS-c, Improves Markers of Liver Injury and Metabolism in Obese Subjects with Nonalcoholic Fatty Liver Disease: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study."

ShowHide Related Items >><<
CWBR CohBar
/

+

CWBR CohBar
/

+

08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
03/31/21 Chardan
CohBar price target raised to $3.50 from $3.00 at Chardan
CWBR CohBar
/

+

Hot Stocks
CohBar appoints Joanne Yun to board of directors » 09:10
09/15/21
09/15
09:10
09/15/21
09:10
CWBR

CohBar

$1.17 /

+ (+0.00%)

CohBar announced the…

CohBar announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. DYun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry. Yun is a partner at Egon Zehnder and is currently a member of the firm's Health Practice. In addition to her board and executive leadership work for global pharmaceutical and biotechnology companies, Yun leads the Research & Development segment of Egon Zehnder's Health Practice.

ShowHide Related Items >><<
CWBR CohBar
$1.17 /

+ (+0.00%)

CWBR CohBar
$1.17 /

+ (+0.00%)

08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
03/31/21 Chardan
CohBar price target raised to $3.50 from $3.00 at Chardan
CWBR CohBar
$1.17 /

+ (+0.00%)

Hot Stocks
CohBar granted U.S. patent covering CB4211 compositions, use » 09:19
09/08/21
09/08
09:19
09/08/21
09:19
CWBR

CohBar

$1.23 /

-0.04 (-3.16%)

CohBar announced the…

CohBar announced the United States Patent and Trademark Office has granted a patent, U.S. No. 11,111,271, covering CohBar's lead candidate CB4211 and related compositions, as well as methods of treatment, including methods of treating nonalcoholic steatohepatitis. The term of the new patent extends to at least 2037, not including any patent term extension to which CohBar may be entitled. Should CB4211 be approved in the United States, the new patent would be eligible for listing in the FDA Orange Book. The new patent further extends CohBar's growing intellectual property portfolio, which now includes 13 issued patents and more than 65 filed applications directed to novel analogs of mitochondrially encoded peptides and methods of treating a variety of diseases.

ShowHide Related Items >><<
CWBR CohBar
$1.23 /

-0.04 (-3.16%)

CWBR CohBar
$1.23 /

-0.04 (-3.16%)

08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
03/31/21 Chardan
CohBar price target raised to $3.50 from $3.00 at Chardan
CWBR CohBar
$1.23 /

-0.04 (-3.16%)

Over a quarter ago
Hot Stocks
CohBar appoints Carol Nast to board of directors » 09:12
08/16/21
08/16
09:12
08/16/21
09:12
CWBR

CohBar

$1.29 /

-0.16 (-11.03%)

CohBar announced the…

CohBar announced the appointment of Carol Nast as an independent director on the company's Board, effective August 11, 2021. Nast has spent her career in executive level positions with both large multinational companies and early-stage companies in the medical industry. Most recently, Ms. Nast served as Chief Operating Officer at MindMed, a biotech company developing psychedelic-inspired therapies.

ShowHide Related Items >><<
CWBR CohBar
$1.29 /

-0.16 (-11.03%)

CWBR CohBar
$1.29 /

-0.16 (-11.03%)

08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
03/31/21 Chardan
CohBar price target raised to $3.50 from $3.00 at Chardan
CWBR CohBar
$1.29 /

-0.16 (-11.03%)

Earnings
CohBar reports Q2 EPS (8c), consensus (6c) » 08:21
08/11/21
08/11
08:21
08/11/21
08:21
CWBR

CohBar

$1.29 /

-0.01 (-0.77%)

CohBar had cash and…

CohBar had cash and investments of $13.8M as of June 30, 2021, compared to $21M as of December 31, 2020. The cash burn for the quarter ended June 30, 2021, was approximately $4.6M.

ShowHide Related Items >><<
CWBR CohBar
$1.29 /

-0.01 (-0.77%)

CWBR CohBar
$1.29 /

-0.01 (-0.77%)

08/11/21 WBB Securities
CohBar upgraded to Buy from Speculative Buy at WBB Securities
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
04/23/21 Maxim
CohBar initiated with a Buy at Maxim
03/31/21 Chardan
CohBar price target raised to $3.50 from $3.00 at Chardan
CWBR CohBar
$1.29 /

-0.01 (-0.77%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.